Multiple Advantages of GLP-1 Agonists in Type 2 Diabetes With Cirrhosis of the Liver
Multiple Advantages of GLP-1 Agonists in Type 2 Diabetes With Cirrhosis of the Liver
NEW OBSERVATIONAL DATA: In people with type 2 diabetes (T2D) and compensated liver cirrhosis, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use reduces the risk for death, cardiovascular disease, decompensated cirrhosis, and liver failure.
METHODOLOGY: Data from Taiwan's National Health Insurance Research Database were used in this population-based cohort study.
467 matched pairs of GLP-1 RA users and nonusers with T2D and compensated liver cirrhosis (mean age, 57) were created using propensity-score matching.
In multivariable-adjusted Cox proportional hazards models, all-cause mortality, cardiovascular events, decompensated cirrhosis, and other important outcomes were compared.
TAKEAWAY: Death rates per 1000 person-years during a mean follow-up of around 3 years were 27.5 in GLP-1 RA users compared
Comments
Post a Comment